Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 956K, Supplementary Figure 1. A, Cellular viability of 6 sensitive and 5 resistant cell lines at 1.0μM rigosertib treatment as measured by SRB assay; Supplementary Figure 2. Proliferation of 2 rigosertib-sensitive (584 and HN11) and 2 rigosertib-resistant (MSK921 and UMSCC19) cell lines; Supplementary Figure 3. Western blot analysis of EGFR pathway activation in vitro in vehicle control (C), 1.0 μM rigosertib (R), and 1.0 μM ZSTK474 (Z) treated cultures; Supplementary Figure 4. A, Representative IHC of orthotopically xenografted HNSCC cell lines. B, Western blot analysis of EGFR pathway activation and representative IHC; Supplemental Figure 5. Graphical representation of tumor growth for the control (♦) and rigosertib (■) treatment groups from the sensitive CUHN026 (A) and resistant CUHN013 (B) tumor lines. Supplemental Figure 6. Western blot analysis of EGFR pathway activation in the control (C) and rigosertib (R) treated direct patient xenografted tissue; Supplemental Figure 7. Representative IHC from treated direct patient xenografted tissue.
Authors: Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles, Magdalena J. Glogowska, David P. Astling, J. Jason Morton, Phuong Le, Adrian Umpierrez, Justin Eagles-Soukup, Gregory N. Gan, Brian W. Vogler, Daniel Sehrt, Sarah M. Takimoto, Dara L. Aisner, Francois Wilhelm, Barbara A. Frederick, Marileila Varella-Garcia, Aik-Choon Tan, Antonio Jimeno
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362478732